Is There an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry Over Somatostatin Receptor Scintigraphy in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response? Abstract #1118

Introduction: It is not known whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value over OctreoScan® uptake in predicting response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Aim(s): The aims were to: 1) establish sst2a positivity in GEP-NET samples of patients who had been treated with PRRT using 177Lu-octreotate, 2) determine the relationship between GEP-NET response to PRRT and tumoral sst2a expression, and 3) compare patients characteristics with sst2a negative and positive tumors.
Materials and methods: We have selected 75 consecutive GEP-NET patients who had undergone PRRT using 177Lu-octreotate and who had follow-up by computed tomography (CT). Tumoral sst2a expression was determined by IHC. Tumor response to CT scans was scored according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Others
Presenting Author: MD Roxanne Van Adrichem
Keywords: sst2a

To read results and conclusion, please login ...

Further abstracts you may be interested in

#186 Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas
Introduction: Endocrine tumors of the digestive tract and pancreas (GEP-NET) are often considered to be associated with other primary malignancies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kimberly Kamp
#274 An Unexpected Diagnosis
Introduction: Paragangliomas (PGL) are defined as rare tumors arising from extra-adrenal sympathetic and parasympathetic paraganglia and malignant paragangliomas are defined by the presence of metastases.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr.ssa Chiara Martini
#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Tao Cui
Authors: Cui T, Ryberg U, Li S C, Cunningham J, ...
#467 Thoracic and Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) and Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS)
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, mostly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence of EAS in the setting of patients diagnosed with thoracic or gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) is virtually absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Drs. Kimberly Kamp
Keywords: ACTH, GEP-NETS, Cushing
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill